Sanofi (SNY) Position Increased by Boston Partners
Boston Partners lifted its stake in Sanofi (NYSE:SNY) by 6.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,664,983 shares of the company’s stock after purchasing an additional 503,799 shares during the period. Boston Partners owned approximately 0.35% of Sanofi worth $431,429,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Parallel Advisors LLC lifted its stake in shares of Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares during the period. YorkBridge Wealth Partners LLC lifted its stake in shares of Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after purchasing an additional 776 shares during the period. Eagle Ridge Investment Management acquired a new stake in shares of Sanofi in the second quarter valued at about $160,000. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Sanofi by 142.8% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares during the period. Finally, Toronto Dominion Bank lifted its stake in shares of Sanofi by 4.6% in the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after purchasing an additional 180 shares during the period. Hedge funds and other institutional investors own 9.36% of the company’s stock.
Several equities analysts have weighed in on SNY shares. Argus restated a “buy” rating and set a $55.00 target price on shares of Sanofi in a report on Friday, September 1st. Zacks Investment Research downgraded shares of Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. HSBC Holdings plc upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. BidaskClub downgraded shares of Sanofi from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $53.50.
Shares of Sanofi (NYSE:SNY) traded up $0.26 during midday trading on Wednesday, hitting $45.84. 512,818 shares of the stock were exchanged, compared to its average volume of 1,500,832. The stock has a market capitalization of $116,165.88, a P/E ratio of 14.53, a PEG ratio of 2.27 and a beta of 0.88. Sanofi has a 1-year low of $38.45 and a 1-year high of $50.65. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/08/sanofi-sny-position-increased-by-boston-partners.html.
In other news, major shareholder Sanofi purchased 105,820 shares of the stock in a transaction dated Thursday, August 24th. The stock was acquired at an average cost of $482.04 per share, for a total transaction of $51,009,472.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.00% of the company’s stock.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.